https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

https://www.nexus.ethz.ch/  

8952 Schlieren, Wagistrasse 18

 +41 44 632 21 61
 stekhoven@nexus.ethz.ch

NEXUS Personalized Health Technologies is an ETH Technology Platform created to enable and accelerate the execution of translational research projects by providing key technological resources, tools and collaboration opportunities for the personalized health research community. NEXUS is built around two interdisciplinary technology units that are staffed with professional scientists: Theragnostics Discovery and Clinical Bioinformatics.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

http://www.biognosys.ch/  

8952 Schlieren, Wagistrasse 21

 +41 44 738 20 40
 info@biognosys.ch

BiognoSYS provides proteomics solutions to scientists and clinicians.

https://www.zh.ch/de/volkswirtschaftsdirektion/amt-fuer-wirtschaft/standortfoerderung.html  

8090 Zürich, Walchestrasse 19

 +41 43 259 49 92
 standort@vd.zh.ch

The Division of Business and Economic Development supports resident companies, promotes Zurich's innovation capacity by way of connecting the relevant stakeholders in key industries, fosters external economic relations and offers guidance to companies interested in moving to Zurich.

https://www.repertoire.com/  

8952 Schlieren, Wagistrasse 27

 info@repertoire.com

The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.